News
Neuroblastoma can be a particularly insidious cancer. In about half of all cases, tumors regress, even without therapy. In ...
After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona ...
A proof-of-concept study finds that donated insulin-producing cells can be genetically modified to avoid provoking the recipient's immune system.
Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...
Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...
Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.
The FDA's approval of the first CRISPR-Cas9–based gene therapy marked a major milestone in biomedicine, validating genome ...
The University of Copenhagen is excited to announce Gordian Biotechnology as a Tier 5 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in ...
A 26-year-old Downriver man seen at Children’s Hospital of Michigan in Detroit since infancy for a rare bleeding disorder in ...
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
Connecticut is now participating in a new federal program aimed at expanding treatment access for patients with sickle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results